Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders.
Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders.
复制标题
DOI：
10.1007/s40265-021-01605-y
复制
发表时间：
2021-10
期刊：
影响因子：
11.5
通讯作者：
Mikelis CM
中科院分区：
文献类型：
--
作者：
Akwii RG;Mikelis CM
抗血管生成方法显著地推进了血管相关病理的治疗。目前基于血管内皮生长因子（VEGF）的抗血管生成治疗的短暂结果和已知的副作用加强了对其他生长因子的研究。血管生成素/Tie（Ang/Tie）家族在血管生理学中具有确定的作用，并调节血管生成、血管通透性和炎症反应。Ang/Tie家族由血管生成素1-4、它们的受体、Tie 1和Tie 2以及血管内皮蛋白酪氨酸磷酸酶（VE-PTP）组成。Tie 2激活的调节在临床前模型中提供了有希望的结果，并导致了针对视网膜疾病的Ang/Tie靶向候选药物的临床试验。虽然对Ang/Tie在肺部疾病中的作用知之甚少，但一些研究已经揭示了Ang/Tie家族成员作为肺血管疾病的药物靶点的巨大潜力。在这篇综述中，我们总结了血管紧张素/Tie通路在视网膜和肺血管生理学和相关疾病中的功能，并强调了目前正在或预计将在视网膜和肺血管疾病的临床评价中靶向该通路的有前途的候选药物。
Anti-angiogenic approaches have significantly advanced the treatment of vascular-related pathologies. The ephemeral outcome and known side effects of the current vascular endothelial growth factor (VEGF)-based anti-angiogenic treatments have intensified research on other growth factors. The angiopoietin/Tie (Ang/Tie) family has an established role in vascular physiology and regulates angiogenesis, vascular permeability, and inflammatory responses. The Ang/Tie family consists of angiopoietins 1–4, their receptors, tie1 and 2 and the vascular endothelial-protein tyrosine phosphatase (VE-PTP). Modulation of Tie2 activation has provided a promising outcome in preclinical models and has led to clinical trials of Ang/Tie-targeting drug candidates for retinal disorders. Although less is known about the role of Ang/Tie in pulmonary disorders, several studies have revealed great potential of the Ang/Tie family members as drug targets for pulmonary vascular disorders as well. In this review, we summarize the functions of the Ang/Tie pathway in retinal and pulmonary vascular physiology and relevant disorders and highlight promising drug candidates targeting this pathway currently being or expected to be under clinical evaluation for retinal and pulmonary vascular disorders.
登录
查看更多内容
血管生成素受体 Tie2 通过调节 COUP-TFII 来实现静脉规范和维护
影响因子：
7.7
作者：
Chu, Man;Li, Taotao;He, Yulong
通讯作者：
He, Yulong
影响因子：
4.4
作者：
Cai, Jun;Kehoe, Oksana;Boulton, Michael E.
通讯作者：
Boulton, Michael E.
影响因子：
4.3
作者：
Ando, Masaru;Miyazaki, Eishi;Kadota, Junichi
通讯作者：
Kadota, Junichi
影响因子：
158.5
作者：
Brown, David M.;Kaiser, Peter K.;Schneider, Susan
通讯作者：
Schneider, Susan
DOI：
10.1186/s13054-020-03398-0
发表时间：
2020-12-14
期刊：
Critical care (London, England)
影响因子：
--
作者：
Bermejo-Martin JF;González-Rivera M;Almansa R;Micheloud D;Tedim AP;Domínguez-Gil M;Resino S;Martín-Fernández M;Ryan Murua P;Pérez-García F;Tamayo L;Lopez-Izquierdo R;Bustamante E;Aldecoa C;Gómez JM;Rico-Feijoo J;Orduña A;Méndez R;Fernández Natal I;Megías G;González-Estecha M;Carriedo D;Doncel C;Jorge N;Ortega A;de la Fuente A;Del Campo F;Fernández-Ratero JA;Trapiello W;González-Jiménez P;Ruiz G;Kelvin AA;Ostadgavahi AT;Oneizat R;Ruiz LM;Miguéns I;Gargallo E;Muñoz I;Pelegrin S;Martín S;García Olivares P;Cedeño JA;Ruiz Albi T;Puertas C;Berezo JÁ;Renedo G;Herrán R;Bustamante-Munguira J;Enríquez P;Cicuendez R;Blanco J;Abadia J;Gómez Barquero J;Mamolar N;Blanca-López N;Valdivia LJ;Fernández Caso B;Mantecón MÁ;Motos A;Fernandez-Barat L;Ferrer R;Barbé F;Torres A;Menéndez R;Eiros JM;Kelvin DJ
通讯作者：
Kelvin DJ